219 related articles for article (PubMed ID: 32437091)
1. Tumor-suppressor Fbxw7 targets SIK2 for degradation to interfere with TORC2-AKT signaling in pancreatic cancer.
Zhang MX; Wang H; Sun GP
Cell Biol Int; 2020 Sep; 44(9):1900-1910. PubMed ID: 32437091
[TBL] [Abstract][Full Text] [Related]
2. Tumor suppressor Fbxw7 antagonizes WNT signaling by targeting β-catenin for degradation in pancreatic cancer.
Jiang JX; Sun CY; Tian S; Yu C; Chen MY; Zhang H
Tumour Biol; 2016 Oct; 37(10):13893-13902. PubMed ID: 27485116
[TBL] [Abstract][Full Text] [Related]
3. Rictor Undergoes Glycogen Synthase Kinase 3 (GSK3)-dependent, FBXW7-mediated Ubiquitination and Proteasomal Degradation.
Koo J; Wu X; Mao Z; Khuri FR; Sun SY
J Biol Chem; 2015 May; 290(22):14120-9. PubMed ID: 25897075
[TBL] [Abstract][Full Text] [Related]
4. Fbxw7 acts as an E3 ubiquitin ligase that targets c-Myb for nemo-like kinase (NLK)-induced degradation.
Kanei-Ishii C; Nomura T; Takagi T; Watanabe N; Nakayama KI; Ishii S
J Biol Chem; 2008 Nov; 283(45):30540-8. PubMed ID: 18765672
[TBL] [Abstract][Full Text] [Related]
5. SIK2 represses AKT/GSK3β/β-catenin signaling and suppresses gastric cancer by inhibiting autophagic degradation of protein phosphatases.
Dai XM; Zhang YH; Lin XH; Huang XX; Zhang Y; Xue CR; Chen WN; Ye JX; Lin XJ; Lin X
Mol Oncol; 2021 Jan; 15(1):228-245. PubMed ID: 33128264
[TBL] [Abstract][Full Text] [Related]
6. Guttiferone K impedes cell cycle re-entry of quiescent prostate cancer cells via stabilization of FBXW7 and subsequent c-MYC degradation.
Xi Z; Yao M; Li Y; Xie C; Holst J; Liu T; Cai S; Lao Y; Tan H; Xu HX; Dong Q
Cell Death Dis; 2016 Jun; 7(6):e2252. PubMed ID: 27253416
[TBL] [Abstract][Full Text] [Related]
7. GSK3-SCF(FBXW7) targets JunB for degradation in G2 to preserve chromatid cohesion before anaphase.
Pérez-Benavente B; García JL; Rodríguez MS; Pineda-Lucena A; Piechaczyk M; Font de Mora J; Farràs R
Oncogene; 2013 Apr; 32(17):2189-99. PubMed ID: 22710716
[TBL] [Abstract][Full Text] [Related]
8. Loss of Fbxw7 synergizes with activated Akt signaling to promote c-Myc dependent cholangiocarcinogenesis.
Wang J; Wang H; Peters M; Ding N; Ribback S; Utpatel K; Cigliano A; Dombrowski F; Xu M; Chen X; Song X; Che L; Evert M; Cossu A; Gordan J; Zeng Y; Chen X; Calvisi DF
J Hepatol; 2019 Oct; 71(4):742-752. PubMed ID: 31195063
[TBL] [Abstract][Full Text] [Related]
9. F-box and WD repeat domain-containing-7 (Fbxw7) protein targets endoplasmic reticulum-anchored osteogenic and chondrogenic transcriptional factors for degradation.
Yumimoto K; Matsumoto M; Onoyama I; Imaizumi K; Nakayama KI
J Biol Chem; 2013 Oct; 288(40):28488-502. PubMed ID: 23955342
[TBL] [Abstract][Full Text] [Related]
10. MYC is a critical target of FBXW7.
Sato M; Rodriguez-Barrueco R; Yu J; Do C; Silva JM; Gautier J
Oncotarget; 2015 Feb; 6(5):3292-305. PubMed ID: 25669969
[TBL] [Abstract][Full Text] [Related]
11. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression.
Mao JH; Kim IJ; Wu D; Climent J; Kang HC; DelRosario R; Balmain A
Science; 2008 Sep; 321(5895):1499-502. PubMed ID: 18787170
[TBL] [Abstract][Full Text] [Related]
12. Plk2 promotes tumor growth and inhibits apoptosis by targeting Fbxw7/Cyclin E in colorectal cancer.
Ou B; Zhao J; Guan S; Wangpu X; Zhu C; Zong Y; Ma J; Sun J; Zheng M; Feng H; Lu A
Cancer Lett; 2016 Oct; 380(2):457-466. PubMed ID: 27423313
[TBL] [Abstract][Full Text] [Related]
13. ERK kinase phosphorylates and destabilizes the tumor suppressor FBW7 in pancreatic cancer.
Ji S; Qin Y; Shi S; Liu X; Hu H; Zhou H; Gao J; Zhang B; Xu W; Liu J; Liang D; Liu L; Liu C; Long J; Zhou H; Chiao PJ; Xu J; Ni Q; Gao D; Yu X
Cell Res; 2015 May; 25(5):561-73. PubMed ID: 25753158
[TBL] [Abstract][Full Text] [Related]
14. Rictor regulates FBXW7-dependent c-Myc and cyclin E degradation in colorectal cancer cells.
Guo Z; Zhou Y; Evers BM; Wang Q
Biochem Biophys Res Commun; 2012 Feb; 418(2):426-32. PubMed ID: 22285861
[TBL] [Abstract][Full Text] [Related]
15. The emerging roles of F-box proteins in pancreatic tumorigenesis.
Wang H; Maitra A; Wang H
Semin Cancer Biol; 2016 Feb; 36():88-94. PubMed ID: 26384530
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA‑223‑induced inhibition of the
Liu Z; Ma T; Duan J; Liu X; Liu L
Mol Med Rep; 2021 Feb; 23(2):. PubMed ID: 33355365
[TBL] [Abstract][Full Text] [Related]
17. FBXW7 is involved in Aurora B degradation.
Teng CL; Hsieh YC; Phan L; Shin J; Gully C; Velazquez-Torres G; Skerl S; Yeung SC; Hsu SL; Lee MH
Cell Cycle; 2012 Nov; 11(21):4059-68. PubMed ID: 23095493
[TBL] [Abstract][Full Text] [Related]
18. FBXO45-MYCBP2 regulates mitotic cell fate by targeting FBXW7 for degradation.
Richter KT; Kschonsak YT; Vodicska B; Hoffmann I
Cell Death Differ; 2020 Feb; 27(2):758-772. PubMed ID: 31285543
[TBL] [Abstract][Full Text] [Related]
19. The FBXW7 tumor suppressor inhibits breast cancer proliferation and promotes apoptosis by targeting MTDH for degradation.
Chen X; Li XY; Long M; Wang X; Gao ZW; Cui Y; Ren J; Zhang Z; Liu C; Dong K; Zhang H
Neoplasma; 2018; 65(2):201-209. PubMed ID: 29534580
[TBL] [Abstract][Full Text] [Related]
20. Fbxw7 Tumor Suppressor: A Vital Regulator Contributes to Human Tumorigenesis.
Cao J; Ge MH; Ling ZQ
Medicine (Baltimore); 2016 Feb; 95(7):e2496. PubMed ID: 26886596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
